Manufacturers/sponsors |
Allos Therapeutic (pralatrexate) |
Others |
Department of Health |
|
NHS Camden |
|
NHS Middlesbrough |
|
Welsh Assembly Government |
Patient/carer groups |
Afiya Trust |
|
African Caribbean Leukaemia Trust (ACLT) |
|
Anthony Nolan Bone Marrow Trust |
|
Black Health Agency |
|
CANCERactive |
|
Cancer Black Care |
|
Cancer 52 |
|
Counsel and Care |
|
Equalities National Council |
|
Helen Rollason Heal Cancer Charity |
|
Leukaemia CARE |
|
Leukaemia Society (UK) |
|
Lymphoma Association |
|
Macmillan Cancer Support |
|
Maggie’s Centres |
|
Marie Curie Cancer Care |
|
Muslim Council of Britain |
|
Muslim Health Network |
|
Rarer Cancers Foundation |
|
South Asian Health Foundation |
|
Specialised Healthcare Alliance |
|
Sue Ryder Care |
|
Tenovus |
Professional groups |
Association of Cancer Physicians |
|
British Association for Services to the Elderly |
|
British Committee for Standards in Haematology |
|
British Geriatrics Society |
|
British Psychosocial Oncology Society |
|
British Society for Haematology |
|
Cancer Networks Pharmacists Forum |
|
Cancer Research UK |
|
Royal College of General Practitioners |
|
Royal College of Nursing |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal Pharmaceutical Society |
|
Royal Society of Medicine |
|
United Kingdom Clinical Pharmacy Association |
|
United Kingdom Oncology Nursing Society |
Associated guideline groups |
National Collaborating Centre for Cancer |
Associated public health groups |
None |
Comparator manufacturers |
Actavis UK (epirubicin, fludarabine, gemcitabine, prednisolone) |
|
Alliance Pharmaceuticals (prednisolone) |
|
Amdipharm (prednisolone) |
|
Auden McKenzie (Pharma Division) (dexamethasone) |
|
Baxter (cyclophosphamide, ifosfamide) |
|
Bristol-Myers Squibb (carboplatin, cisplatin, etoposide) |
|
Chemidex pharma (dexamethasone) |
|
Eli Lilly and Company (gemcitabine) |
|
Genzyme Therapeutics (fludarabine) |
|
Goldshield Critical Care (cisplatin) |
|
Hameln Pharmaceuticals (epirubicin) |
|
Hospira UK (carboplatin, cisplatin, cytarabine, epirubicin, etoposide, fludarabine, gemcitabine) |
|
Medac UK (epirubicin, etoposide, gemcitabine, lomustine) |
|
Merck Sharp & Dohme (dexamethasone) |
|
Mylan (epirubicin, gemcitabine) |
|
Pfizer (cisplatin, cyclophosphamide, cytarabine, epirubicin, methylprednisolone) |
|
Rosemont Pharmaceuticals (dexamethasone) |
|
Sandoz (carboplatin, cisplatin, epirubicin, fludarabine, gemcitabine) |
|
Sigma Pharmaceuticals (methylprednisolone) |
|
Sun Pharmaceuticals UK (carboplatin, gemcitabine) |
|
Teva UK (carboplatin, cisplatin, epirubicin, etoposide, fludarabine, gemcitabine) |
|
Wockhardt UK (carboplatin, cisplatin, epirubicin, fludarabine, gemcitabine) |
Evidence Review Group |
British Medical Journal (BMJ) |
|
National Institute for Health Research Health Technology Assessment Programme |
General |
Board of Community Health Councils in Wales |
|
British National Formulary |
|
Commissioning Support Appraisals Service |
|
Department of Health,Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
National Association of Primary Care |
|
NHS Alliance |
|
NHS Commercial Medicines Unit |
|
NHS Confederation |
|
Public Health Wales NHS Trust |
|
Scottish Medicines Consortium |
Relevant research groups |
British National Lymphoma Investigation |
|
Elimination of Leukaemia Fund |
|
Institute of Cancer Research |
|
Leukaemia Busters |
|
Leukaemia & Lymphoma Research |
|
MRC Clinical Trials Unit |
|
National Cancer Research Institute |
|
National Cancer Research Network |
|
National Institute for Health Research |
|
Policy Research Institute on Ageing and Ethnicity |
|
Research Institute of the Care of Older People |